Novel drug regimen can improve stem cell transplantation outcomes
Monday, December 9, 2013 - 15:00
in Health & Medicine
Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers.